The inhibition of factor VIII by autoantibody development, or acquired hemophilia, occurs in
approximately one person per million each year and can cause life-threatening bleeding …

Focuses on clinical features, laboratory diagnosis, prognostic factors and therapeutic
management of patients with acquired hemophilia. Association of acquired hemophilia with …

Acquired hemophilia A (AHA) is caused by autoantibodies against factor VIII (FVIII).
Immunosuppressive treatment (IST) results in remission of disease in 60% to 80% of …

Acquired hemophilia A (AHA) is an autoimmune disease caused by an autoantibody to
factor VIII. Patients are at risk of severe and fatal hemorrhage until the inhibitor is eradicated …

Background The life expectancy of non‐severe hemophilia A (HA) patients equals the life
expectancy of the non‐hemophilic population. However, data on the effect of inhibitor …

Objectives: Acquired hemophilia is a rare disease caused by the development of
autoantibodies against factor VIII. Since 1981 we have observed 17 patients with this …

Acquired hemophilia A (AHA), a rare bleeding disorder caused by neutralizing
autoantibodies against coagulation factor VIII (FVIII), occurs in both men and women without …

Patients with acquired hemophilia remain at risk for severe hemorrhage until their inhibitors
are permanently eradicated. Concurrent with bleed management, immunomodulation …

Acquired haemophilia A is an auto‐immune disease caused by an inhibitory antibody to
factor VIII. Patients with an acquired factor VIII inhibitor are at risk of life‐and limb …

Abstract Background Acquired hemophilia A (AHA) is a rare bleeding disorder caused by an
autoantibody to coagulation factor (F) VIII. It is characterized by soft tissue bleeding in …